Targeted Pathway Inhibition in Patients With Pancreatic Cancer

NCT04005690 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Stage II Pancreatic Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8
Unresectable Pancreatic Ductal Adenocarcinoma
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Resectable Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Cobimetinib
DRUG: Olaparib
DRUG: Onvansertib
DRUG: Azenosertib
DRUG: Saruparib
BIOLOGICAL: Tremelimumab

Sponsor

OHSU Knight Cancer Institute

Collaborators

American Association for Cancer Research
Oregon Health and Science University
Genentech, Inc.
Cardiff Oncology